Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice
T cells, ultimately amplifying immune responses to radiotherapy. Moreover, immune checkpoint blockade further augments the antitumor efficacy of engineered BCG combined with radiotherapy. Here, we show that trained immunity in tumor-associated macrophages is a promising strategy to sensitize glioblastoma to radiotherapy and improve treatment outcomes.
Authors
- Haishi Qiao (ORCID: https://orcid.org/0000-0002-7751-7652)
- Lizhou Jia (ORCID: https://orcid.org/0000-0003-0645-1868)
- Ziyang Yuan (ORCID: https://orcid.org/0000-0001-7644-4706)
- Ningyi Ma
- Liang Qin (ORCID: https://orcid.org/0000-0002-6501-1953)
- Tai Yang (ORCID: https://orcid.org/0000-0002-2145-7435)
- Ningyi Sun
- Ke Ren (ORCID: https://orcid.org/0009-0001-5317-9820)
- Dahai Yu (ORCID: https://orcid.org/0000-0002-1108-1809)
- Xu Ying
- Ziyuan Xiao
- Lei Lei
- Guodong Wang
- Zhiyong Chang
Institutions
- Nanjing University of Chinese Medicine (CN)
- China Pharmaceutical University (CN)
- Chengdu Medical College (CN)
- Hetao College (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
- Jiangsu Province Hospital (CN)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-04-20
- DOI
- https://doi.org/10.1038/s41467-026-72067-7
- Primary Topic
- Immune responses and vaccinations
- Type
- article
- Field-Weighted Citation Impact
- 0.00